Immuneering Corp
corporate_fare Company Profile
Immuneering Corp (NASDAQ:IMRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for IMRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for IMRX spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- Immuneering Extends Cash Runway to Q4 2028 as Phase 3 Pancreatic Trial Enrollment Runs Ahead of Schedule
- Immuneering Extends Cash Runway to Q4 2028 as Phase 3 Enrollment Runs Ahead of Schedule
- Atebimetinib Data Show Weight Preservation Doubles Survival in Pancreatic Cancer
- Immuneering Q2 2026: $182.7M Cash, Phase 3 Pancreatic Cancer Trial Underway, 17.3-Month Survival Data
- Atebimetinib Preclinical Data Published in Cancer Research Shows Broad Activity and Favorable Tolerability
Financial Snapshot
Short Interest & Short Volume
19.20 days to coverFINRA reported short interest of 14,595,733 shares in IMRX as of the October 30, 2026 settlement, a 10.6% decrease from the prior period — about 19.2 days to cover at its recent average daily volume. On November 20, 2026, 32.6% of IMRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.